JP2002500619A5 - - Google Patents

Download PDF

Info

Publication number
JP2002500619A5
JP2002500619A5 JP1997529620A JP52962097A JP2002500619A5 JP 2002500619 A5 JP2002500619 A5 JP 2002500619A5 JP 1997529620 A JP1997529620 A JP 1997529620A JP 52962097 A JP52962097 A JP 52962097A JP 2002500619 A5 JP2002500619 A5 JP 2002500619A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997529620A
Other languages
English (en)
Other versions
JP2002500619A (ja
Filing date
Publication date
Priority claimed from US08/799,616 external-priority patent/US5846990A/en
Application filed filed Critical
Publication of JP2002500619A publication Critical patent/JP2002500619A/ja
Publication of JP2002500619A5 publication Critical patent/JP2002500619A5/ja
Ceased legal-status Critical Current

Links

Description

Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
Figure 2002500619
JP52962097A 1996-02-20 1997-02-20 置換ビフェニルイソオキサゾールスルホンアミド Ceased JP2002500619A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60397596A 1996-02-20 1996-02-20
US08/603,975 1996-02-20
US75471596A 1996-11-21 1996-11-21
US08/754,715 1996-11-21
US08/799,616 1997-02-13
US08/799,616 US5846990A (en) 1995-07-24 1997-02-13 Substituted biphenyl isoxazole sulfonamides
PCT/US1997/003956 WO1997029748A1 (en) 1996-02-20 1997-02-20 Substituted biphenyl isoxazole sulfonamides

Publications (2)

Publication Number Publication Date
JP2002500619A JP2002500619A (ja) 2002-01-08
JP2002500619A5 true JP2002500619A5 (ja) 2004-11-04

Family

ID=27416891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52962097A Ceased JP2002500619A (ja) 1996-02-20 1997-02-20 置換ビフェニルイソオキサゾールスルホンアミド

Country Status (9)

Country Link
US (1) US5846990A (ja)
EP (1) EP0921800B1 (ja)
JP (1) JP2002500619A (ja)
AT (1) ATE264324T1 (ja)
AU (1) AU720458B2 (ja)
CA (1) CA2240043A1 (ja)
DE (1) DE69728673T2 (ja)
ES (1) ES2219762T3 (ja)
WO (1) WO1997029748A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JP2001523218A (ja) * 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HU227183B1 (en) 1997-04-28 2010-09-28 Encysive Pharmaceuticals Inc Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
CN1123342C (zh) * 1997-10-17 2003-10-08 欧洲基因有限公司 肾素-血管紧张素系统的抑制剂的用途
DE19813354A1 (de) * 1998-03-26 1999-09-30 Bayer Ag Arylphenylsubstituierte cyclische Ketoenole
DE69940063D1 (de) * 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
HUP0201320A2 (en) * 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
JP2003520785A (ja) * 1999-12-15 2003-07-08 ブリストル−マイヤーズ スクイブ カンパニー アンジオテンシン・エンドセリン受容体二重拮抗薬としてのビフェニルスルホンアミド類
CA2395684C (en) 1999-12-31 2012-01-03 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JP2004501083A (ja) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US6639082B2 (en) * 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002072088A2 (en) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Gk 활성제로서의 아미드 유도체
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
MXPA05000130A (es) * 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
DE60327446D1 (de) * 2002-10-10 2009-06-10 Arena Pharm Inc 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7273866B2 (en) * 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US20070197492A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
EP1633351A1 (en) * 2003-06-13 2006-03-15 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
CA2530589A1 (en) * 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
DE10337497A1 (de) * 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-Biphenylsubstituierte-Pyrazolidin-3,5-dion-Derivate
CN102516240A (zh) * 2004-01-06 2012-06-27 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
EP1732523B9 (en) 2004-03-30 2010-06-02 Relypsa, Inc. Potassium binding polymers and uses thereof
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US7999114B2 (en) * 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
EP1904466A1 (en) * 2005-07-08 2008-04-02 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
CA2615938C (en) 2005-07-14 2014-04-29 Novo-Nordisk A/S Urea glucokinase activators
GB2446076B (en) * 2005-09-30 2010-11-24 Ilypsa Inc Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
CA2624170C (en) 2005-09-30 2014-02-25 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
US20100010035A1 (en) * 2006-03-03 2010-01-14 Ramesh Chandra Gupta Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
PT2365988E (pt) * 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2012117097A1 (en) * 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
KR20210005314A (ko) 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
AU2022306778A1 (en) * 2021-07-09 2024-01-18 Vicore Pharma Ab New selective angiotensin ii compounds
WO2023224963A1 (en) * 2022-05-16 2023-11-23 Aria Pharmaceuticals, Inc. Dual-acting angiotensin and endothelin receptor antagonists
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法
CN115677511B (zh) * 2022-10-26 2024-06-21 南通华祥医药科技有限公司 一种2,2-二氟丙胺盐酸盐的合成方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB804036A (en) * 1956-03-02 1958-11-05 Hoffmann La Roche A process for the manufacture of a sulphanilamide of the isoxazole series
CH364506A (de) * 1956-09-04 1962-09-30 Shionogi & Co Verfahren zur Herstellung des therapeutisch wirksamen 3-Sulfanilamido-5-methyl-isoxazols
DE1059459B (de) * 1956-09-04 1959-06-18 Shionogi & Co Verfahren zur Herstellung des therapeutisch wertvollen 3-Sulfanilamido-5-methylisoxazols
US2888455A (en) * 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
GB897440A (en) * 1960-02-08 1962-05-30 Shionogi & Co Improvements in or relating to sulfonamides
GB1473433A (ja) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
EP0076072B1 (en) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH & Co. KG Sulphonamides
US4661479A (en) * 1982-02-19 1987-04-28 Merck And Co., Inc. Bicyclic lactams as antihypertensives
EP0194548A3 (de) * 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
CA2005741C (en) * 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
US5082838A (en) * 1989-06-21 1992-01-21 Takeda Chemical Industries, Ltd. Sulfur-containing fused pyrimidine derivatives, their production and use
DK0443983T3 (da) * 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
WO1991015479A1 (en) * 1990-03-30 1991-10-17 Merck & Co., Inc. Substituted pyrazoles, isoxazoles and isothiazoles
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
TW270116B (ja) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
PL176250B1 (pl) * 1991-11-05 1999-05-31 Smithkline Beecham Corp Sposób wytwarzania pochodnych indanu
SE9103397D0 (sv) * 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
TW224462B (ja) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TW215434B (ja) * 1992-03-07 1993-11-01 Hoechst Ag
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
AU4376893A (en) * 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
TW287160B (ja) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0617001B1 (en) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
FI941826A (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
PT634175E (pt) * 1993-07-15 2001-06-29 Hoffmann La Roche Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CA2168154A1 (en) * 1995-02-06 1996-08-07 Natesan Murugesan Substituted biphenyl sulfonamide endothelin antagonists
DE19509950A1 (de) * 1995-03-18 1996-09-19 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
KR100359396B1 (ko) * 1995-04-04 2003-03-15 텍사스 바이오테크놀로지 코포레이션 엔도텔린의활성을조절하는티에닐-,푸릴-및피롤릴설폰아미드및이의유도체
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
JP2001523218A (ja) * 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe

Similar Documents

Publication Publication Date Title
JP2000510730A5 (ja)
JP2000502280A5 (ja)
JP2000501771A5 (ja)
JP2000501599A5 (ja)
JP2000501018A5 (ja)
JP2000500076A5 (ja)
JP2000501324A5 (ja)
JP2000500026A5 (ja)
JP2000502472A5 (ja)
JP2000501338A5 (ja)
JP2000501825A5 (ja)
JP2000500874A5 (ja)
JP2000502485A5 (ja)
JP2000501774A5 (ja)
JP2000502425A5 (ja)
JP2000502570A5 (ja)
JP2000500912A5 (ja)
JP2000502568A5 (ja)
JP2000501876A5 (ja)
JP2000501744A5 (ja)
JP2000502316A5 (ja)
JP2000500857A5 (ja)
JP2000502714A5 (ja)
JP2000501229A5 (ja)
JP2000500318A5 (ja)